Gunma University | Date: 2017-02-08
An existing ultrasonic diagnostic device is used to obtain a color flow image of a target object whose stiffness is to be measured. At this time, a vibration exciter applies a micro vibration with a frequency of n/4 (n represents an odd number equal to or larger than 1) to the target object with respect to a burst frequency of an ultrasonic pulse to generate a shear elastic wave. As a result, a striped pattern corresponding to the stiffness of the target object caused by the shear elastic wave appears on a display of the ultrasonic diagnostic device as a shear elastic wave detection image.
Tohoku University, Gunma University and Fuso Pharmaceutical Industries Ltd. | Date: 2017-01-04
The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), m, n, p, X, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.
Nisshinbo Holdings Inc. and Gunma University | Date: 2017-04-19
Provided are a carbon catalyst, an electrode, and a battery that exhibit excellent activity. A carbon catalyst according to one embodiment of the present invention has a carbon structure in which area ratios of three peaks f_(broad), f_(middle), and f_(narrow) obtained by separating a peak in the vicinity of a diffraction angle of 26 in an X-ray diffraction pattern obtained by powder X-ray diffraction satisfy the following conditions (a) to (c) : (a) f_(broad): 75% or more and 96% or less; (b) f_(middle): 3.2% or more and 15% or less; and (c) f_(narrow) : 0.4% or more and 15% or less.
News Article | May 9, 2017
Asia Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Asia proton therapy market is anticipated to almost three-fold during the period 2016 - 2022. The number of proton therapy centers is continuously increasing in Asia. Still, it is believed that players will miss out on a majority of cancer patients who can benefit with proton therapy, overlooking a huge multi-Billion-dollar potential market. The number of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are huge. Key Points Covered in the Report: - Asia accounts for around 60% of the world population and half the global burden of cancer. - Mitsubishi is the leading player in proton therapy market in Japan. However, other players like IBA, Hitachi, Sumitomo etc. have also started to make their presence felt in the market. - South Korea is the second largest market for proton therapy in Asia. - China has the huge market opportunity for proton therapy treatment owing to large population bae of cancer patients. - IBA has one operational proton therapy center in China while 4 more centers are in development phase. - In India, 2 proton therapy centers are under development phase and are scheduled to open in 2018 and 2019. Key Topics Covered: 1. Executive Summary 2. Asia Proton Therapy Market Analysis 2.1 Asia Proton Therapy Market - Actual and Potential Market 2.2 Asia Proton Therapy Patient Number - Actual and Potential 3. Asia Proton Therapy Market Share Analysis 3.1 Asia Proton Therapy Actual and Potential Market Share - By Country 3.2 Asia Proton Therapy Actual and Potential Candidate Share - By Country 4. Asia - List of Proton Therapy Centers, Start of Treatment, Patient Treated 5. Japan Proton Therapy Market Analysis 5.1 Japan Proton Therapy - Actual and Potential Market (2003 - 2022) 5.2 Japan Proton Therapy Patients Number - Actual and Potential (2003 - 2022) 5.3 Japan - List of Proton Therapy Centers, Cost, Start of Treatment, Patient Treated 5.4 Japan Proton Therapy - Company Analysis 6. Japan - Number of Patients Treated at Proton Therapy Centers 6.1 National Institute of Radiological Sciences - Number of Patients Treated (2008 - 2015) 6.2 Hyogo Ion Beam Medical Center - Number of Patients Treated (2007 - 2015) 6.3 Shizuoka Cancer Center - Number of Patients Treated (2007 - 2015) 6.4 Southern Tohoku Proton Therapy Center - Number of Patients Treated (2013 - 2014) 6.5 Gunma University Heavy Ion Medical Center - Number of Patients Treated (2013 - 2015) 6.6 Fukui Prefectural Hospital Proton Beam Cancer Treatment Center - Number of Patients Treated (2013 - 2015) 6.7 Medipolis Medical Research Institute - Number of Patients Treated (2013 - 2015) 6.8 Saga Heavy Ion Medical Accelerator in Tosu - Number of Patients Treated (2013 - 2015) 6.9 Japanese National Cancer Center - Number of Patients Treated (2007 - 2014) 6.10 The Proton Medical Research Center 2, University of Tsukuba, JAPAN - Number of Patients Treated (2007 - 2015) 6.11 Nagoya City Quality Life 21 Jouhoku, Japan - Number of Patients Treated (2013 - 2015) 6.12 Aizawa Hospital - Number of Patients Treated (Oct - 2014) 7. South Korea Proton Therapy Market Analysis 7.1 South Korea Proton Therapy - Actual and Potential Market (2007 - 2022) 7.2 South Korea Proton Therapy Patients Number - Actual and Potential (2007 - 2022) 7.3 South Korea - List of Proton Therapy Centers, Start of Treatment, Patient Treated 8. South Korea - Number of Patients Treated at Proton Therapy Centers 8.1 Korean National Cancer Center - Number of Patients Treated (2007 - 2015) 8.2 Samsung Proton Center - Number of Patients Treated (2015) 9. China Proton Therapy Market Analysis 9.1 China Proton Therapy - Actual and Potential Market (2014 - 2022) 9.2 China Proton Therapy Patients Number - Actual and Potential (2014 - 2022) 9.3 China - List of Proton Therapy Centers, Start of Treatment 10. China - Number of Patients Treated at Proton Therapy Centers 10.1 Wanjie Proton Therapy Center (WPTC) - Number of Patients Treated (2007 - 2013) 11. India Potential Proton Therapy Market Analysis (2009 - 2022) 11.1 India - Potential Proton Therapy Market and Forecast 11.2 India - Potential Candidate for Proton Therapy Number and Forecast 11.3 India - List of Proton Therapy Centers, Start of Treatment 12. Singapore Potential Proton Therapy Market Analysis (2012 - 2022) 12.1 Singapore - Potential Proton Therapy Market and Forecast 12.2 Singapore - Potential Candidate for Proton Therapy Number and Forecast 12.3 Singapore - List of Proton Therapy Centers, Start of Treatment 13. Taiwan Potential Proton Therapy Market Analysis (2012 - 2022) 13.1 Taiwan - Potential Proton Therapy Market and Forecast 13.2 Taiwan - Potential Candidate for Proton Therapy Number and Forecast 13.3 Taiwan - List of Proton Therapy Centers, Start of Treatment 14. Current Radiation Therapies 14.1 Third Dimensional Conformal Therapy (CRT) 14.2 Image Guided Radiotherapy (IGRT) 14.3 Intensity Modulated Radiotherapy (IMRT) 14.4 Stereotactic Radiotherapy 14.5 Neutron Therapy 14.6 Heavy Ion Radiotherapy 14.7 Proton Therapy 15. Components of a Standard Proton Therapy Center 15.1 Proton Accelerator 15.2 Beam Transport System 15.3 Beam Delivery System 15.4 Nozzle 15.5 Treatment Planning System 15.6 Image Viewers 15.7 Patient Positioning System (PPS) 15.8 Human Resource 16. Proton Therapy - Driving Factors 16.1 Technology Advancement 16.2 Growing Incidence of Cancer Patients 16.3 Proton Therapy Provides Enormous Benefits 17. Proton Therapy - Challenges 17.1 Requires Huge Investment 17.2 Operations Challenges 17.3 More Clinical Evidence Is Needed For more information about this report visit http://www.researchandmarkets.com/research/8hcbbg/asia_proton Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asia-proton-therapy-market-report-2017-patients-treated-list-of-proton-therapy-centers-and-forecast-to-2022---research-and-markets-300454204.html
Tohoku University, Gunma University and Fuso Pharmaceutical Industries Ltd. | Date: 2016-01-13
Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.
Ito K.,Gunma University
Nature Reviews Urology | Year: 2014
Prostate cancer incidence and mortality in most native Asian populations have gradually increased, but are around one-third lower than in corresponding Asian-American cohorts, which are themselves lower than the rates observed in other American cohorts. Although genetic and environmental factors, particularly a Western diet, could partially explain these differences, lower exposure to PSA screening in Asian individuals might be a major contributing factor. Genetic features and diet are, however, unlikely to differ substantially within the same region of Asia, and age-stratified PSA levels in men from various Asian countries are almost identical; therefore, variation in the epidemiology of prostate cancer among native Asian populations might be attributable to differences in access to PSA testing, urology clinics, and available therapies. Conversely, the proportion of patients with metastatic prostate cancer is substantially higher even in the more developed Asian countries than in migratory Asian populations residing in Western countries and in Westerners. Consequently, the most appropriate approaches to the management of prostate cancer in Asian countries probably also differ, and therefore individualized prostate cancer screening and treatment strategies based on the epidemiological features and socioeconomic status of each country are needed. © 2014 Macmillan Publishers Limited. All rights reserved.
Okajima F.,Gunma University
Cellular Signalling | Year: 2013
Under ischemic and inflammatory circumstances, such as allergic airway asthma, rheumatoid arthritis, atherosclerosis, and tumors, extracellular acidification occurs due to the stimulation of anaerobic glycolysis. An acidic microenvironment has been shown to modulate pro-inflammatory or anti-inflammatory responses, including cyclooxygenase-2 (COX-2) expression, prostaglandin synthesis, and cytokine expression, in a variety of cell types, and thereby to exacerbate or ameliorate inflammation. However, molecular mechanisms underlying extracellular acidic pH-induced actions have not been fully understood. Recent studies have shown that ovarian cancer G protein-coupled receptor 1 (OGR1)-family G protein-coupled receptors (GPCRs) can sense extracellular pH or protons, which in turn stimulates intracellular signaling pathways and subsequent diverse cellular responses. In the present review, I discuss extracellular acidic pH-induced inflammatory responses and related responses in inflammatory cells, such as macrophages and neutrophils, and non-inflammatory cells, such as smooth muscle cells and endothelial cells, focusing especially on proton-sensing GPCRs. © 2013 Elsevier Inc.
Gunma University | Date: 2016-11-02
Provided is an implantable spacer that can be placed in a body and can be easily removed after placement. The implantable spacer includes a tube which is folded or bent at one or a plurality of positions to form partial sections adjacent to each other; fixing threads which are disposed along a direction transverse to the partial sections in order to maintain the shape of the tube; and a trigger thread for catching the fixing threads being in a releasable state.
Japan National Institute of Advanced Industrial Science, Technology, Gunma University and Alps Electric | Date: 2016-03-22
An electroconductive film for an actuator is formed from a gel composition including carbon nanofibers, an ionic liquid, and a polymer. The carbon nanofibers are produced with an aromatic mesophase pitch by melt spinning.
Kitamura T.,Gunma University
Nature Reviews Endocrinology | Year: 2013
Over the past two decades, insulin resistance has been considered essential to the aetiology of type 2 diabetes mellitus (T2DM). However, insulin resistance does not lead to T2DM unless it is accompanied by pancreatic β-cell dysfunction, because healthy β cells can compensate for insulin resistance by increasing in number and functional output. Furthermore, β-cell mass is decreased in patients with diabetes mellitus, suggesting a primary role for β-cell dysfunction in the pathogenesis of T2DM. The dysfunction of β cells can develop through various mechanisms, including oxidative, endoplasmic reticulum or hypoxic stress, as well as via induction of cytokines; these processes lead to apoptosis, uncontrolled autophagy and failure to proliferate. Transdifferentiation between β cells and α cells occurs under certain pathological conditions, and emerging evidence suggests that β-cell dedifferentiation or transdifferentiation might account for the reduction in β-cell mass observed in patients with severe T2DM. FOXO1, a key transcription factor in insulin signalling, is implicated in these mechanisms. This Review discusses advances in our understanding of the contribution of FOXO1 signalling to the development of β-cell failure in T2DM. © 2013 Macmillan Publishers Limited. All rights reserved.